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INTRODUCTION
The microenvironment of the liver has a strong immune regulatory 
capacity, thereby controlling responses to antigens derived from 
the blood or intestinal uptake.1 When compared to other solid organ 
transplants, this ability to exert immune tolerance is a major advan-
tage in liver transplantation, requiring much lesser use of immune 
suppressive drugs. However, the partially immune suppressive 
environment of the liver attenuates immune responses against liver 
tumors and can also be exploited by viral pathogens, resulting in 
chronic infections such in hepatitis B or C.2 In gene therapy, one 
can take advantage of these unique immunological features to pro-
mote sustained therapeutic gene expression. The capacity of liver-
directed gene transfer to induce immune tolerance to transgene 
products has been demonstrated for several diverse viral vectors 
such as lentivirus or adeno-associated virus (AAV).1,3–6 Expression of 
an antigen in hepatocytes can induce peripheral tolerance through 
induction of CD4+CD25+FoxP3+ regulatory T cells (Treg).7 In case of a 
secreted transgene product that may reach the thymus through the 
circulation, central tolerance mechanisms may also apply.8
High levels of hepatic transgene expression increase Treg 
induction and favor immune tolerance, resulting in suppression 
of antibody and T cell responses at extrahepatic sites as well.9–12 
Therefore, induced liver tolerance may become dominant over 
activation of immune responses in other tissues or to systemically 
delivered antigens. Hence, hepatic gene transfer is in development 
for immune tolerance induction for inherited protein deficiencies 
and is also considered as an immune modulatory therapy for auto-
immune disease and allergies.4,13–15 For example, antibody (“inhibi-
tor”) formation against coagulation factors in the treatment of 
hemophilia could be prevented and even reversed in murine and 
canine models.10,16–18 In addition to Treg induction, direct inhibition 
of memory B cells by high antigen levels likely contributed to these 
successes.10 Another example for a potential application of this 
approach is gene therapy for Pompe disease. Here, gene transfer to 
muscle in order to replace the lysosomal storage enzyme GAA (acid 
α-glucosidase) bears a risk of immune responses to GAA that can be 
suppressed by simultaneous hepatic gene transfer.19–21
The mechanism of liver gene transfer-induced immune tolerance 
has been extensively studied over the past years.4 Both induction 
and maintenance of tolerance are dependent on Treg.10 Induction of 
transgene product-specific Treg requires TGF-β and is in part depen-
dent on the GITR – GITR-L costimulatory pathway.22–24 Expression of 
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The tolerogenic hepatic microenvironment impedes clearance of viral infections but is an advantage in viral vector gene transfer, 
which often results in immune tolerance induction to transgene products. Although the underlying tolerance mechanism has 
been extensively studied, our understanding of antigen presentation to transgene product-specific CD4+ T cells remains limited. To 
address this, we administered hepatotropic adeno-associated virus (AAV8) vector expressing cytoplasmic ovalbumin (OVA) into wt 
mice followed by adoptive transfer of transgenic OVA-specific T cells. We find that that the liver-draining lymph nodes (celiac and 
portal) are the major sites of MHC II presentation of the virally encoded antigen, as judged by in vivo proliferation of DO11.10 CD4+ 
T cells (requiring professional antigen-presenting cells, e.g., macrophages) and CD4+CD25+FoxP3+ Treg induction. Antigen presen-
tation in the liver itself contributes to activation of CD4+ T cells egressing from the liver. Hepatic-induced Treg rapidly disseminate 
through the systemic circulation. By contrast, a secreted OVA transgene product is presented in multiple organs, and OVA-specific 
Treg emerge in both the thymus and periphery. In summary, liver draining lymph nodes play an integral role in hepatic antigen 
presentation and peripheral Treg induction, which results in systemic regulation of the response to viral gene products.
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the cytokine IL-10 by Treg or Kupffer cells helps to suppress CD8+ 
T cell responses in the liver but may not be required for suppres-
sion of antibody formation.22,25 In addition to Treg induction, other 
mechanisms contribute to shifting the balance from an effector to 
a regulated response. These include both Fas-FasL-dependent and 
-independent programmed cell death and T cell anergy.8,26 All these 
events require presentation of transgene product-derived antigen 
by MHC II to CD4+ T cells. However, much less is known about this 
aspect. Previously, we found a requirement for both dendritic cells 
(DC) and macrophages/Kupffer cells (KCs) for in vivo presentation 
to CD4+ T cells specific to the transgene product expressed from 
an AAV vector upon hepatic gene transfer.10 Others found that liver 
sinusoidal endothelial cells (LSEC) are capable of acquiring hepa-
tocyte-derived antigens and inducing Treg.27 There is an ongoing 
debate in the field about the role of antigen presentation in the 
liver itself as opposed to in lymphoid organs. In order to be able to 
identify sites of antigen presentation and track activation of CD4+ 
T cells and induction of Treg, we designed experiments using T cell 
receptor-transgenic CD4+ T cells with specificity to a cytoplasmic 
protein expressed from AAV vector upon hepatic gene transfer. We 
identify the celiac and portal lymph nodes as a major site of trans-
gene product presentation to CD4+ T cells induction but also found 
evidence for CD4+ T cell activation in the liver itself. Activated CD4+ 
T cell egress and then re-enter liver and lymphoid organs. Further, 
CD4+CD25+FoxP3+ Treg were peripherally induced, initially in the 
liver draining lymph nodes, and rapidly disseminated through the 
blood, representing one mechanism by which hepatic gene transfer 
establishes systemic tolerance even to nonsecreted proteins. These 
data have implications for development of hepatic gene transfer 
and for immune responses to viral infections of the liver.
ReSUlTS
Secreted ovalbumin antigen is presented to specific CD4+ T cells in 
multiple organs following hepatic AAV8 gene transfer
AAV8 expressing a secreted Ovalbumin (Ova) transgene was admin-
istered intravenously to wt BALBc mice (Figure 1a). This vector has 
strong liver tropism and is highly effective in transduction of murine 
hepatocytes in vivo.28,29 After 2 weeks, half of the mice were given 
gadolinium chloride, which specifically inactivates Kupffer cells 
and M1 macrophages.30 Gadolinium chloride was injected i.p. at 
10 mg/kg on day 13 and 14 after AAV8-Ova administration. On day 
14, Ova-specific CD4+ T cells labeled with CellTrace Violet dye were 
adoptively transferred into all mice. These CD4+ T cells had been 
isolated from BALB/c mice that are transgenic for the Ova-specific 
T cell receptor (TCR) DO11.10.8,31 Five days after adoptive transfer, 
livers and spleens were collected, and single cell suspensions were 
analyzed by flow cytometry. Substantial proliferation of DO11.10-tg 
CD4+ T cells was observed in both tissues. This was significantly 
decreased in mice receiving gadolinium chloride (Figure 1b). This 
experiment was repeated but this time numerous additional lym-
phoid tissues were analyzed by flow cytometry. Substantial pro-
liferation of adoptively transferred DO11.10 CD4+ T cells is readily 
detected in all tissues surveyed. Proliferation was highest in liver 
and spleen, as would be expected for a protein expressed in sys-
temic circulation. After inactivation of Kupffer cells and M1 macro-
phages, proliferation was most dramatically reduced in liver and 
spleen, while all other organs (except for the mesenteric lymph 
node) also showed a reduction in the average rate of proliferation 
(Figure 1c). Taken together, the data indicate that professional APCs, 
and in particular Kuppfer cells/macrophages, are required for pre-
sentation of transgene-derived antigen to CD4+ T cells.
Gene delivery of cytoplasmic Ova induces proliferation primarily in 
specific liver-draining lymph nodes
In spite of the strong liver tropism of AAV8, using a secreted transgene 
product did not allow us to pinpoint the location of presentation of 
hepatic expressed antigen, because of dissemination to multiple 
organs via the systemic circulation. In order to determine where hepatic 
(rather than systemically) expressed antigen is MHC II presented, we 
employed an AAV8 vector that expresses nonsecreted, cytoplasmic 
Ova (Cyto-Ova). DO11.1 CD4+ T cells labeled with CellTrace Violet were 
adoptively transferred into wt BALBc mice that had previously been 
transduced with AAV8-Cyto-Ova. We then assessed proliferation of the 
donor DO11.10 CD4+ T cells in liver, spleen and various lymph nodes, 
including celiac and portal lymph nodes (which are both located just 
Figure 1  Proliferation of adoptively transferred Ova-specific DO11.10-
tg CD4+ T cells in wt BALBc mice transduced with AAV-Ova (expressing 
secreted Ova) with or without inactivation of Kupffer cells and M1 
macrophages via gadolinium chloride (GdCl). (a) Experimental plan. 
BALBc mice were transduced with 1 × 1011 vg of AAV8-Ova vector. After 
2 weeks, half of the mice are given GdCl, followed by adoptive transfer 
of DO11.10-tg CD4+ T cells labeled with CellTrace Violet dye to all mice. 
Proliferation of transferred cells was measured by flow cytometry 
5 days later. (b) Representative examples of proliferation of transferred 
cells in the spleen and the liver with or without GdCl treatment (n = 3/
experimental group). (c) Proliferation in liver, spleen, and different lymph 
nodes in a repeat experiment (n = 5–7/experimental group). Naive: Mice 
that received neither vector nor GdCl. Data are average ± SD. **P < 0.01, 
***P < 0.0001.
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outside the liver where the hepatic portal vein enter) (Figure 2b).32,33 
To allow for antibody staining and flow cytometry, we combined cells 
from celiac and portal lymph nodes,34 i.e., the liver-draining lymph 
nodes. As shown in Figure 2a, antigen presentation occurred chiefly 
in the draining lymph nodes of the liver and not in other lymph nodes 
or other organs such as spleen or liver. Administering of gadolinium 
chloride caused a substantial decrease in proliferation (Figure 2a). 
Therefore, a similar requirement for professional APCs exists for pre-
sentation of cytoplasmic or secreted transgene product. We conclude 
that the transgene product, whether cytoplasmic or secreted, has to 
be taken up by professional APCs for MHC II presentation that is ade-
quate to induce CD4+ T cell proliferation.
Whereas initial activation of Ova-transgene-specific CD4+ T cells 
occurs in the liver and liver-draining lymph nodes, antigen-induced 
Treg distribute through the systemic circulation
An alternative method to detect antigen presentation is to assay for 
expression of early activation markers in the T cells. AAV8-Cyto-Ova 
was injected into DO11-10-tg Rag-2-/- BALB/c mice. Due to targeted 
deletion of recombinase activating gene 2 (rag-2), these mice lack 
endogenous rearranged TCRs. However, transgenic expression 
of the DO11.10 TCR assures that CD4+ T cells develop, which are 
all Ova-specific. Furthermore, these mice lack naturally occurring 
nTreg.28,35–37 Upon hepatic gene transfer, upregulation of the early 
activation marker CD69+ in CD4+ T cells was shown first and pre-
dominately in the liver and liver-draining celiac/portal lymph nodes 
(Figure 3a). This CD4+ T cell activation remained highest over time 
in these locations, implicating these tissues as the primary sites of 
antigen presentation leading to CD4+ T cell activation. On the other 
hand, induced regulatory T cells (iTreg) were seen early on in all tis-
sues surveyed at a similar level, except for the blood, which showed 
higher Treg frequencies early on (Figure 3b). At later time points, 
Treg were found in all tissues, with the celiac/portal lymph nodes 
and liver showing the highest frequencies. We conclude that the 
liver and its draining lymph nodes are major sites of early activation 
of transgene product-specific CD4+ T cells, as well as sites for accu-
mulation of activated CD4+ T cells and iTreg. Furthermore, the data 
suggests that iTreg rapidly disseminate through the blood.
Blocking lymphocyte mobilization reveals sites of initial CD4+ 
activation, egression, and re-entry to immune organs
The experiment with AAV8-Cyto-Ova in DO11-10-tg Rag-2-/- BALB/c 
mice was repeated with the following modification. Starting 1 week 
after gene transfer, half of the mice were additionally given daily 
doses of FTY720 for 1 week, followed by tissue harvest (Figure 4a). 
FTY720 prevents the upregulation of Sphingosine 1-phosphate 
Figure 2 Proliferation of adoptively transferred DO11.10-tg CD4+ T cells in 
wt BALB/c mice transduced with AAV-Cyto-Ova (expressing cytoplasmic 
Ova) with or without inactivation of Kupffer cells and M1 macrophages 
via gadolinium chloride. The experimental timeline was identical to that 
in Figure 1. (a) Proliferation in liver, spleen, and different lymph nodes 
(n = 5–6/experimental group). Naive: Mice that received neither vector 
nor GdCl. Data are average ± SD. **P < 0.01. (b) Location of the liver 
draining celiac and portal lymph nodes in a BALB/c mouse. Anatomical 
structures are indicated to the right.
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Figure 3 Frequencies of activated CD69+CD4+ T cells (a) and of 
CD4+CD25+FoxP3+ iTreg (b) in different tissues after as a function of 
time after AAV8-Cyto-Ova administration to DO11.10-tg Rag-2-/- BALB/c 
mice (1 × 1012 vg/mouse, n = 3–6/time point), as determined by flow 
cytometry. Data are average ± SD.
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(SIP) adhesion molecules, inhibiting lymphocyte migration, though 
still allowing T cell activation.38–40 Two weeks after gene transfer, 
elevated frequencies of CD69+CD4+ T cells were again found pre-
dominately in the liver and celiac/portal lymph nodes in control 
mice not receiving FTY720 (Figure 4b). FTY720 treatment, to “lock” 
activated CD4+ T cells in place, again resulted elevated frequencies 
of CD69+CD4+ T cells in the liver. Frequencies remained unchanged 
and high in liver-draining lymph nodes (Figure 4b). This result sug-
gests that activated CD4+ T cells more rapidly egress from the liver 
than from the draining nodes. However, these do not accumulate in 
peripheral circulation, as no activated T cells were found in circula-
tion (data not shown).
By 3 weeks after gene transfer (Figure 4c), frequencies of 
CD69+CD4+ T cells had further increased in liver, celiac/portal nodes, 
and spleens of control mice (Figure 4d). When the 1-week regimen 
with FTY was performed starting 2 weeks after gene transfer, fol-
lowed by flow cytometric analysis, the frequencies of activated 
CD4+ T cells in liver, liver-draining lymph nodes, and spleens were 
significantly reduced compared to control mice. Therefore, at this 
later time point, activated Ova-specific CD4+ T cells in these tissues 
in part represented cells that had by now re-entered lymphoid 
organs and the liver.
Induction of Cyto-ova-specific Treg occurs exclusively extra-thymic 
and at least in part in liver-draining lymph nodes
Consistent with our previous studies, we find Treg emerging at low 
frequency in the thymus after hepatic gene transfer of secreted Ova 
(Figure 5a).7,8 This was in addition to the more pronounced induction 
of iTreg in liver and secondary lymphoid organs (data not shown). 
In contrast, Treg were largely undetectable in the thymus when ana-
lyzed 5 weeks after delivery of Cyto-Ova (Figure 5a). At this time, the 
Treg frequency in spleen and blood in response to Cyto-Ova was 
about half of that achieved with secreted Ova. Since peripherally 
induced iTreg already appear by ~3 weeks after AAV-Cyto-Ova gene 
transfer, we sought to determine their origin using the same experi-
mental protocol outlined in Figure 4c, which is to block T cell migra-
tion during the third week after gene transfer with FTY720. Drug 
treatment significantly increased the frequency of iTreg in the liver-
draining lymph nodes (but not other organs, Figure 5b), suggesting 
that these nodes are also major sites of Treg induction to hepatic 
expressed transgene product.
DISCUSSION
Antigen presentation is a critical part of an adaptive immune 
response and also of tolerance induction to a specific antigen. The 
architecture and composition of liver provide an environment that 
often promotes immune tolerance.41 For example, APC residing in 
sinusoids such as KCs and LSEC allow for antigen presentation to 
T cells present in the blood. The liver also contains a larger num-
ber of plasmacytoid DCs than other organs. These have important 
innate immune functions but also facilitate Treg induction, possibly 
via expression of IDO (Indoleamine-pyrrole 2,3-dioxygenase).35,42 
Expression of immune-suppressive cytokines such as IL-10 and neg-
ative regulators of T cell activation such as PD-L1 (Programmed cell 
Death-Ligand 1) further contribute to a tolerogenic environment.2 
Hence, gene therapy based on expression in the liver is an excel-
lent approach to induce immune tolerance to a transgene product. 
AAV vectors, characterized by eliciting only low and transient innate 
immunity and by inefficient transduction of professional APCs, are 
ideal for this purpose.43–45 However, other vector systems, such as 
microRNA-regulated integrating and integration-deficient lentiviral 
vectors, have also been highly effective in tolerance induction.5,6 
Although critical to liver tolerance induction, surprisingly little is 
known about presentation of the expressed antigen to CD4+ T cells. 
The study presented here fills some of these gaps in knowledge. Our 
findings are also viral infections of the liver such as with HBV or HCV.
Figure 4 Frequencies of activated CD69+CD4+ T cells in different tissues of DO11.10-tg Rag-2-/- BALB/c mice after AAV8-Cyto-Ova administration with 
or without FTY720 treatment (to block T cell migration). Vector was given to all mice on day 0. (a, b) Experiment 1: Half of the mice were given daily 
injections of FTY720 from d7 to d13, followed by flow cytometric analysis on day 14 to determine frequencies of CD69+CD4+ T cells. (c, d) Experiment 
2: Half of the mice were given daily injections of FTY720 from d14 to d20, followed by flow cytometric analysis on day 21 to determine frequencies of 
CD69+CD4+ T cells. Data are average ± SD for n = 3–5/experimental group. **P < 0.01.
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Liver-draining lymph nodes as a major site of antigen presentation
Because of the unique composition and location of APCs in hepatic 
environment, it has been thought that antigen presentation in 
the liver itself leads to T cell activation and to Treg induction. This 
model is in contrast to the classical view of T cell activation in drain-
ing lymph nodes that provide immune surveillance for the organ. 
Consistent with this second model, we find that liver-draining 
lymph nodes are the major site of presentation of an antigen 
expressed in hepatocytes after AAV gene transfer, leading to CD4+ 
T cell proliferation. Nonetheless, in the DO11-10-tg Rag-2-/- model, 
we find a substantial increase in activated CD4+ T cells in the liver 
when T cell migration is blocked. Thus, the liver itself is likely also a 
site of MHC II presentation of hepatocyte-expressed antigen, lead-
ing to activation of CD4+ T cells that rapidly egress from the liver. We 
conclude that CD4+ T cells are activated the liver and in celiac/portal 
lymph nodes within the first 2 weeks after gene transfer. They sub-
sequently egress and re-enter lymphoid tissues, with many return-
ing to the liver and liver-draining nodes. Our data suggest that the 
liver is a site where CD4+ T activation but only limited proliferation 
takes place. Others found that AAV8 gene transfer upregulated FasL 
on transduced hepatocytes, thereby increasing T cell apoptosis.26 
Hence, the liver environment may favor activation-induced cell 
death over CD4+ T cell proliferation.
MHC II presentation of cytoplasmic or secreted antigen expressed 
from an AAV upon hepatic gene transfer, leading to CD4+ T cell prolif-
eration, depended on macrophages. Performing hepatic AAV8-Ova 
gene transfer for expression of secreted Ova, we previously found 
that CD11chi DCs were also required, in addition to macrophages.10 
Together, these findings show that professional APCs, likely both 
macrophages and DCs, are required for antigen presentation. Thus, 
it is likely that nonsecreted antigens are also passed on from hepa-
tocytes to professional APCs. Resident macrophages (e.g., KCs) 
may help capture antigen, which is transported by DCs to draining 
lymph nodes for presentation to induce T cell proliferation. Indeed, 
celiac and portal lymph nodes have been identified as preferential 
sites of migration for DCs injected under the liver capsule, resulting 
in T cell activation in these nodes.32
Induced Treg disseminate systemically
In response to hepatic delivery of a cytoplasmic antigen, iTreg 
were extrathymically induced. Therefore, extrathymic presenta-
tion of hepatocyte-derived antigen leads to conversion of con-
ventional CD4+ T cells to FoxP3+ Treg. Literature data show that 
ectopic expression of an antigen in the liver of a transgenic mouse 
can lead to immune tolerance induction the absence of thymic 
T cell education through Treg induction.46,47 Although induced 
Treg may accumulate in the liver, as shown after hepatic lentivi-
ral gene transfer, they also reside in the lymphoid organs such as 
the spleen, as shown by adoptive transfer of suppression.5–7,10,12,25,48 
A number of studies have documented that liver gene transfer 
induces systemic immune tolerance, even to nonsecreted anti-
gens.5,6,9,10,16,19,47–49 This feature makes liver gene transfer attractive 
as a tolerogenic immune modulatory therapy for multiple diseases. 
Our data show that liver-draining lymph nodes are a major site of 
Treg induction. The celiac/portal lymph nodes are not only sites 
for Treg induction to hepatic but also to orally administered anti-
gen.50 This may reflect transport of antigen from the small intes-
tine to the liver via the portal circulation, followed by transport to 
the celiac/portal nodes by migrating DC. We cannot entirely rule 
out that Treg induction in the liver itself also occurred in our stud-
ies. Others have for example shown that LSEC, a liver-resident cell 
type with the ability to present antigen, are more potent inducers 
of Treg than liver DCs or KCs.27 The advantage of Treg induction in 
sinusoids would be direct and rapid dissemination into the blood 
to establish systemic tolerance.
Interestingly, the blood contained the initially highest frequency 
of induced Treg. Rapid systemic distribution of induced Treg explains 
why immune tolerance can be established when nonhepatic AAV 
gene transfer is performed concomitant with hepatic gene trans-
fer.19,21,49 Increased levels of transgene expression in hepatocytes 
correlate with increased Treg responses. Here, we had to use higher 
vector doses to induce Treg to cytoplasmic compared to secreted 
Ova antigen. As antigen presentation requires uptake by APCs, it 
is possible that secretion facilitates presentation. However, in prior 
studies we and others were able to induce Treg/tolerance with mod-
est expression levels of non-secreted antigens in the liver.6,48,51 While 
such dose responses likely vary depending on the antigen and the 
host, TCR transgenic models may also overestimate the amount of 
antigen required because many cells with identical receptor com-
pete for the antigen.
While a nonsecreted protein expressed in the liver will be sub-
ject to local mechanisms of antigen presentation, it should be 
pointed out that a secreted protein that is distributed via the sys-
temic circulation is be presented in multiple tissues, which may 
include the thymus. It is therefore likely that peripheral Treg induc-
tion in extra-hepatic sites contributes to tolerance induction to a 
secreted protein, and that central tolerance mechanisms, including 
Figure 5 Peripheral induction of Treg in liver draining lymph nodes 
after AAV8-Cyto-Ova gene transfer. (a) Flow cytometric analysis of 
CD4+CD25+Foxp3+ Treg in the thymus 5 weeks after AAV8-Ova (1 × 1011 
vg/mouse) or AAV8-Cyto-Ova (1 × 1012 vg/mouse) administration. In 
contrast to AAV8-Ova administration, which results in systemic delivery 
of secreted Ova and emergence of Treg in the thymus, AAV8-Cyto-Ova 
induced Treg are not found in the thymus. Data are average ± SD for 
n = 5–6/experimental group. (b) Frequencies of peripherally induced 
CD4+CD25+Foxp3+ T cells 3 weeks after AAV-Cyto-Ova administration. 
Half of the mice were given daily injections of FTY720 from d14 to d20, 
followed by flow cytometric analysis on day 21. Data are average ± SD for 
n = 3/experimental group. *P < 0.05, **P < 0.001, ***P < 0.0001.
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thymus-derived Treg, are additionally involved in response to trans-
gene products secreted by hepatocytes into the blood.
Conclusions
In conclusion, liver draining lymph nodes play an integral role in 
presentation of virally encoded antigens in presentation to CD4+ 
T cells. This is particularly the case for non-secreted antigens, which 
are not distributed via the blood. Celiac and portal nodes are the 
major site of antigen presentation and are also a main site of iTreg 
induction. These iTreg rapidly disseminate to other organs through 
the blood, which explains why local immune tolerance induction in 
the hepatic environment can lead to a dominant systemic tolerance 
(summarized in Figure 6). Hence, liver gene transfer is being devel-
oped not only for phenotypic correction of genetic disease but also 
as an immune modulatory therapy for antigen-specific tolerance 
induction.
MATeRIAlS AND MeTHODS
Animals
All mice used in this study were 8-week-old male mice. BALBc mice were 
from Jackson Lab (Bar Harbor, ME). DO11-10-tg Rag-2-/- BALB/c mice were 
from our in house-breeding colony housed at the University of Florida as 
previously described.7,28,35 These mice are immune deficient, while their CD4+ 
T cells exclusively express the DO11.10 TCR specific for the model antigen 
ovalbumin. Immune-competent DO11.10 mice for the adoptive transfer 
experiments were purchased from Jackson Lab. All experiments were per-
formed with a minimum of n = 3 animals per group.
Vectors and animal experiments
AAV coding for secreted ovalbumin (AAV-Ova) was as published.7,8,28 In this 
expression cassette, Ova is under transcriptional control of the human EF1α 
promoter. AAV-Cyto-Ova vector was constructed by replacing the Ova cDNA 
with a sequence coding for a nonsecreted, cytoplasmic version of ovalbumin 
(obtained from Addgene, Cambridge, MA). Vector genomes were packaged 
into AAV serotype 8 capsids by triple transfection of HEK-293 cells. Vector par-
ticles were purified by iodixanol gradient centrifugation, and vector titers were 
determined by dot blot hybridization and confirmed by Western blot using a 
reference standard of known titer for comparison. Vectors were administered 
to mice intravenously via the tail vein using doses that induce Ova-specific 
Treg in DO11-10-tg Rag-2-/- BALB/c mice (1 × 1011 vg/mouse for AAV8-Ova and 
1 × 1012 vg/mouse for AAV8-Cyto-Ova). CellTrace Violet (Invitrogen, Eugene, 
OR) labeling was performed per the manufacturers recommended protocol. 
Briefly, cells were labeled at a final cell density of 3 million cells/ml and a final 
CellTrace Violet concentration of 3 μmol/l in phosphate buffered saline (PBS) 
containing 1% fetal bovine serum (FBS). These cells were then adoptively 
transferred into the host mouse via tail vein. Gadolinium chloride (Sigma, St. 
Louis, MO) was administered intraperitoneally at a dose of 10 mg/kg in PBS. 
FTY720 (Cayman Chemical, Ann Arbor, MI) was administered intraperitoneally 
at a dose of 10 mg/kg in sterile tissue culture grade water.
Tissue harvesting and processing
DO11.10 CD4+ T cells were harvested from the spleens of DO11.10-tg mice 
and transported in L-15 media on ice. These spleens were pushed through 
a 70-micron mesh tube top cell strainer and washed with PBS. CD4+ T cells 
were isolated using a MACS CD4-negative selection column (Miltenyi Biotec, 
Auburn, CA) per manufactures suggested protocols. Livers, spleens, and 
lymph nodes were harvested at indicated time points and transported in 
L-15 media on ice. Tissues were pushed through 70-micron mesh tube top 
cell strainer, washed with PBS to get single cell suspensions.
Flow cytometry
Antibodies against cell surface markers: CD3, CD4, CD69, CD25, DO11.10, 
and the intracellular marker Foxp3 were purchased from eBioscience (San 
Diego, CA). Intracellular Staining kit was also from eBioscience and used per 
the manufacturers protocol. Data was collected with a BD LSR II cytometer 
and data generated using FACS Diva software (BD Biosciences, San Jose, 
CA). Flow cytometry gating schemes are summarized in Supplementary 
Figure S1.
Statistical analysis
Statistical significance was determined with an unpaired, two-tailed 
Student’s t-test using GraphPad Prism 5 software (GraphPad Software, 
La Jolla, CA). Values at P < 0.05 were deemed significant and indicated as 
follows: *P < 0.05, **P < 0.01, ***P < 0.0001.
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